Abstract

The ribosome-associated quality-control (RQC) pathway degrades aberrant nascent polypeptides arising from ribosome stalling during translation. In mammals, the E3 ligase Pirh2 mediates the degradation of aberrant nascent polypeptides by targeting the C-terminal polyalanine degrons (polyAla/C-degrons). Here, we present the crystal structure of Pirh2 bound to the polyAla/C-degron, which shows that the N-terminal domain and the RING domain of Pirh2 form a narrow groove encapsulating the alanine residues of the polyAla/C-degron. Affinity measurements in vitro and global protein stability assays in cells further demonstrate that Pirh2 recognizes a C-terminal A/S-X-A-A motif for substrate degradation. Taken together, our study provides the molecular basis underlying polyAla/C-degron recognition by Pirh2 and expands the substrate recognition spectrum of Pirh2.

Incompletely synthesized nascent polypeptides resulting from ribosome stalling during translation are under surveillance by ribosome-associated quality control. Here, the authors report the molecular mechanism by which the E3 ligase Pirh2 targets the polyalanine tail of aberrant nascent chains for degradation via the C-degron pathway.

Details

Title
Recognition of an Ala-rich C-degron by the E3 ligase Pirh2
Author
Wang, Xiaolu 1 ; Li, Yao 2   VIAFID ORCID Logo  ; Yan, Xiaojie 2   VIAFID ORCID Logo  ; Yang, Qing 3 ; Zhang, Bing 3   VIAFID ORCID Logo  ; Zhang, Ying 4 ; Yuan, Xinxin 3 ; Jiang, Chenhao 4 ; Chen, Dongxing 5   VIAFID ORCID Logo  ; Liu, Quanyan 6 ; Liu, Tong 7 ; Mi, Wenyi 8   VIAFID ORCID Logo  ; Yu, Ying 1   VIAFID ORCID Logo  ; Dong, Cheng 9   VIAFID ORCID Logo 

 Tianjin Medical University, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Haihe Laboratory of Cell Ecosystem, School of Basic Medical Sciences, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University, Department of Pharmacology, Tianjin Key Laboratory of Inflammatory Biology, Center for Cardiovascular Diseases, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228) 
 Tianjin Medical University, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Haihe Laboratory of Cell Ecosystem, School of Basic Medical Sciences, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University, Department of Biochemistry and Molecular Biology, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228) 
 Tianjin Medical University, Department of Biochemistry and Molecular Biology, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228) 
 Tianjin Medical University, Department of Immunology, Tianjin Institute of Immunology, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228) 
 Tianjin Medical University, Department of Medicinal Chemistry, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228) 
 Tianjin Medical University General Hospital, Department of Hepatobiliary Surgery, Tianjin, China (GRID:grid.412645.0) (ISNI:0000 0004 1757 9434) 
 Second Hospital of Tianjin Medical University, Department of Cardiology, Tianjin Institute of Cardiology, Tianjin, China (GRID:grid.412648.d) (ISNI:0000 0004 1798 6160) 
 Tianjin Medical University, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Haihe Laboratory of Cell Ecosystem, School of Basic Medical Sciences, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University, Department of Immunology, Tianjin Institute of Immunology, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228) 
 Tianjin Medical University, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Haihe Laboratory of Cell Ecosystem, School of Basic Medical Sciences, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University, Department of Biochemistry and Molecular Biology, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University General Hospital, Department of Hepatobiliary Surgery, Tianjin, China (GRID:grid.412645.0) (ISNI:0000 0004 1757 9434); Second Hospital of Tianjin Medical University, Department of Cardiology, Tianjin Institute of Cardiology, Tianjin, China (GRID:grid.412648.d) (ISNI:0000 0004 1798 6160) 
Pages
2474
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2807562842
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.